Molecular characterization of rpoB gene mutations in isolates from tuberculosis patients in Cubal, Republic of Angola

被引:10
作者
Rando-Segura, Ariadna [1 ]
Aznar, Maria Luisa [2 ,3 ]
Moreno, Maria Milagros [3 ]
Espasa Soley, Mateu [1 ]
Sulleiro Igual, Elena [1 ]
Bocanegra Garcia, Cristina [2 ,3 ]
Gil Olivas, Eva [2 ,3 ]
Nindia Eugenio, Arlete [3 ]
Escartin Huesca, Carlos [1 ]
Zacarias, Adriano [3 ]
Vegue Collado, Josep [1 ]
Katimba, Domingos
Vivas Cano, Maria Carmen [1 ]
Gabriel, Estevao [3 ]
Lopez Garcia, Maria Teresa [3 ]
Pumarola Sune, Tomas [1 ]
Molina Romero, Israel [2 ]
Tortola Fernandez, Maria Teresa [1 ]
机构
[1] Univ Autonoma Barcelona, PROSICS Barcelona, Vall Dhebron Univ Hosp, Microbiol Dept, Passeig Vall Hebron 119-129, Barcelona 08035, Spain
[2] Univ Autonoma Barcelona, Vall Dhebron Univ Hosp, Infect Dis Dept, PROSICS Barcelona, Barcelona, Spain
[3] Hosp Nossa Senhora Paz, Cubal, Angola
关键词
Angola; Cubal; GenoType MTBDRplus VER2; 0; Resistance; Rifampicin; rpoB mutations; RIFAMPICIN-RESISTANCE; ISONIAZID RESISTANCE; DRUG-RESISTANCE; CULTURE-SYSTEM; DISCORDANCE; FUTURE; ASSAYS;
D O I
10.1186/s12879-021-06763-8
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background The importance of Mycobacterium tuberculosis strains with disputed rpoB mutations remains to be defined. This study aimed to assess the frequency and types of rpoB mutations in M. tuberculosis isolates from Cubal, Angola, a country with a high incidence of tuberculosis. Methods All isolates included (n = 308) were analyzed using phenotypic drug susceptibility testing and GenoType MTBDRplus assay. DNA sequencing of the rpoB gene and determination of rifampicin MIC by macrodilution method were additionally performed on isolates yielding discordant results (n = 12) and those in which the mutation detected was not characterized (n = 8). Results In total, 85.1% (74/87) of rifampicin-resistant strains had undisputed rpoB mutations -S450L (49), D435V (15), H445D (3), H445Y (2), Q432ins (1), L449M plus S450F (1), S450F (1), S450W (1) and S450Y (1)-; 10.3% (9/87) had disputed rpoB mutations-L430P plus S493L (1), N437del (1), H445L (3), D435Y (2), L452P (2)-, 2.3% (2.3%) showed no rpoB mutations and 2.3% (2/87) showed heteroresistance-D435Y plus L452P and L430P plus S493L-. Conclusion Disputed rpoB mutations were common, occurring in 10.3% of rifampicin resistant isolates. Current phenotyping techniques may be unable to detect this resistance pattern. To increase their sensitivity, a lower concentration of RIF could be used in these tests or alternatively, rpoB mutations could be screened and characterized in all M. tuberculosis strains.
引用
收藏
页数:7
相关论文
共 29 条
  • [1] Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis
    Al-Mutairi, Noura M.
    Ahmad, Suhail
    Mokaddas, Eiman
    Eldeen, Hanaa S.
    Joseph, Susan
    [J]. BMC INFECTIOUS DISEASES, 2019, 19 (1)
  • [2] Isolation of Mycobacterium tuberculosis Strains with a Silent Mutation in rpoB Leading to Potential Misassignment of Resistance Category
    Alonso, Maria
    Jose Palacios, Juan
    Herranz, Marta
    Penedo, Ana
    Menendez, Angela
    Bouza, Emilio
    Garcia de Viedma, Dario
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2011, 49 (07) : 2688 - 2690
  • [3] Andre E, 2017, CLIN MICROBIOL INFEC, V23, P167, DOI [10.1016/j.cmi.2016.09.006, 10.1016]
  • [4] Occurrence of rpoB Mutations in Isoniazid-Resistant but Rifampin-Susceptible Mycobacterium tuberculosis Isolates from Germany
    Andres, Soenke
    Hillemann, Doris
    Ruesch-Gerdes, Sabine
    Richter, Elvira
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (01) : 590 - 592
  • [5] [Anonymous], 2020, Global tuberculosis report 2020
  • [6] Isoniazid resistance and the future of drug-resistant tuberculosis
    Cohen, T
    Becerra, MC
    Murray, MB
    [J]. MICROBIAL DRUG RESISTANCE, 2004, 10 (04) : 280 - 285
  • [7] Rifampin Heteroresistance in Mycobacterium tuberculosis Cultures as Detected by Phenotypic and Genotypic Drug Susceptibility Test Methods
    Folkvardsen, Dorte Bek
    Thomsen, Vibeke O.
    Rigouts, Leen
    Rasmussen, Erik Michael
    Bang, Didi
    Bernaerts, Gertjan
    Werngren, Jim
    Toro, Juan Carlos
    Hoffner, Sven
    Hillemann, Doris
    Svensson, Erik
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2013, 51 (12) : 4220 - 4222
  • [8] What Is Resistance? Impact of Phenotypic versus Molecular Drug Resistance Testing on Therapy for Multi-and Extensively Drug-Resistant Tuberculosis
    Heyckendorf, Jan
    Andres, Soenke
    Koser, Claudio U.
    Olaru, Ioana D.
    Schon, Thomas
    Sturegard, Erik
    Beckert, Patrick
    Schleusener, Viola
    Kohl, Thomas A.
    Hillemann, Doris
    Moradigaravand, Danesh
    Parkhill, Julian
    Peacock, Sharon J.
    Niemann, Stefan
    Lange, Christoph
    Merker, Matthias
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (02)
  • [9] How should discordance between molecular and growth-based assays for rifampicin resistance be investigated?
    Hofmann-Thiel, S.
    Hoffmann, H.
    Hillemann, D.
    Rigouts, L.
    Van Deun, A.
    Kranzer, K.
    [J]. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2017, 21 (07) : 721 - 726
  • [10] Hu PL, 2019, J CLIN MICROBIOL, V57, DOI [10.1128/JCM.01707-18, 10.1128/jcm.01707-18]